Drug Profile
SAR 422459
Alternative Names: ABCA4 gene therapy; ATP-binding transporter gene therapy; SAR-422459; Stargardt disease gene therapy - Oxford BioMedica/Sanofi; StarGenLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Oxford BioMedica
- Developer Oxford BioMedica; Sanofi
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action ATP-binding cassette transporter replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Stargardt disease